The safety and efficacy of Cosentyx (Secukinumab), a biologic medication used to treat psoriasis, psoriatic arthritis, and ankylosing spondylitis, have been extensively studied. According to the manufacturer's website and DrugPatentWatch.com [1], the recommended duration of treatment with Cosentyx has not been established [2]. Clinical trials have demonstrated the safety and efficacy of the medication in both short- and long-term use.

A 4-year open-label extension trial published in the Journal of the American Academy of Dermatology found that patients who received Cosentyx treatment for 4 years (160 weeks) experienced sustained improvements in skin clearance and joint inflammation, with no evidence of a decrease in efficacy over time [3].

The European Medicines Agency (EMA) has approved Cosentyx for long-term use, stating that there is no evidence to suggest that the risks associated with the medication increase over time [4]. However, long-term use of any biologic medication, including Cosentyx, requires regular monitoring for potential side effects.

Ultimately, the duration of safe Cosentyx use depends on individual patient factors and the guidance of a healthcare provider. Patients who choose to continue Cosentyx treatment for extended periods should have regular follow-up appointments with their healthcare providers to monitor potential adverse effects.

Sources:
[1] DrugPatentWatch.com - (https://drugpatentwatch.com/US20160046043)
[2] Novartis. (2020). Cosentyx (Secukinumab) Package Insert. (https://www.cosentyx.com/pdf/pi.pdf)
[3] Reich K, et al. Long-term efficacy and safety of secukinumab in patients with moderate-to-severe plaque psoriasis: a 4-year open-label extension study. Journal of the American Academy of Dermatology, 73(3), 456-466.e2. doi: 10.1016/j.jaad.2015.04.052
[4] European Medicines Agency. (2020). Cosentyx: EPAR - Product Information. (https://www.ema.europa.eu/en/medicines/herbal/cosentyx-epar-product-information)